Roberto Labianca

39.1k total citations · 13 hit papers
323 papers, 21.9k citations indexed

About

Roberto Labianca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Roberto Labianca has authored 323 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Oncology, 137 papers in Pulmonary and Respiratory Medicine and 77 papers in Pathology and Forensic Medicine. Recurrent topics in Roberto Labianca's work include Colorectal Cancer Treatments and Studies (154 papers), Gastric Cancer Management and Outcomes (87 papers) and Genetic factors in colorectal cancer (65 papers). Roberto Labianca is often cited by papers focused on Colorectal Cancer Treatments and Studies (154 papers), Gastric Cancer Management and Outcomes (87 papers) and Genetic factors in colorectal cancer (65 papers). Roberto Labianca collaborates with scholars based in Italy, France and United States. Roberto Labianca's co-authors include Giordano Beretta, Daniel J. Sargent, Bernard Nordlinger, Mario Mandalà, Eric Van Cutsem, Stefania Mosconi, Alberto Zaniboni, Richard M. Goldberg, Stefano Cascinu and Sandro Barni and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Roberto Labianca

316 papers receiving 21.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

2010 1.1k citations Daniel J. Sargent, Silvia Marsoni et al. Journal of Clinical Oncology profile →
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013 1.1k citations Roberto Labianca, Bernard Nordlinger et al. Annals of Oncology profile →
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

2009 893 citations Sabine Tejpar, Mauro Delorenzi et al. Journal of Clinical Oncology profile →
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

1998 786 citations Eric Van Cutsem, Emilio Bajetta et al. profile →
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

2005 760 citations Roberto Labianca, Maria Giulia Zampino et al. Journal of Clinical Oncology profile →
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?

2004 756 citations Daniel J. Sargent, Roberto Labianca et al. Journal of Clinical Oncology profile →
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Guillem Argilés, Josep Tabernero et al. Annals of Oncology profile →
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients

2001 719 citations Daniel J. Sargent, Roberto Labianca et al. profile →
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

2005 520 citations Daniel J. Sargent, Marc Buyse et al. Journal of Clinical Oncology profile →
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

2009 446 citations Sandro Barni, Roberto Labianca et al. profile →
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

2011 402 citations Nathan R. Foster, Stephen N. Thibodeau et al. profile →
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

2014 386 citations Stefano Cascinu, Roberto Labianca et al. profile →
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

2013 376 citations Roberto Labianca, Irene Floriani et al. profile →

Peers

Countries citing papers authored by Roberto Labianca

Since Specialization

Citations

This map shows the geographic impact of Roberto Labianca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Labianca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Labianca more than expected).

Fields of papers citing papers by Roberto Labianca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Labianca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Labianca. The network helps show where Roberto Labianca may publish in the future.

Co-authorship network of co-authors of Roberto Labianca

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Labianca. A scholar is included among the top collaborators of Roberto Labianca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Labianca. Roberto Labianca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2020 ·Annals of Oncology ·Guillem Argilés, Josep Tabernero, Roberto Labianca, Daniel Hochhauser, Ramón Salazar, Timothy Iveson, Pierre Laurent‐Puig, Philip Quirke, Takayuki Yoshino, Julien Taı̈eb, Erika Martinelli, Dirk Arnold	736
2	399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial 2020 ·Annals of Oncology ·Gerardo Rosati, Francesca Galli, Sara Lonardi, Katia Dotti, Monica Ronzoni, Maria Giulia Zampino, Maria Banzi, Valeria Pusceddu, Felice Pasini, Silvia Bozzarelli, Nicoletta Pella, Carla Codecà, Vincenzo Montesarchio, Andrea Mambrini, Alfonso De Stefano, L. Ciuffreda, Sara Elena Rebuzzi, Domenico Bilancia, Roberto Labianca	1
3	The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? 2018 ·Annals of Oncology ·Alberto Sobrero, Axel Grothey, Timothy Iveson, Roberto Labianca, Takayuki Yoshino, Julien Taı̈eb, Tim Maughan, Marc Buyse, Thierry André, Jeffrey A. Meyerhardt, Anthony F. Shields, Ioannis Souglakos, J.-Y. Douillard, Andrés Cervantes	27
4	Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients 2017 ·Annals of Oncology ·Fabio Gelsomino, Valter Torri, Alberto Zaniboni, Roberto Labianca, (unknown), Davide Poli, L. Frontini, Stefano Cascinu	2
5	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 2015 ·Clinical Colorectal Cancer ·Nicola Personeni, Lorenza Rimassa, Claudio Verusio, Sandro Barni, Luca Rubino, Silvia Bozzarelli, Eugenio Villa, Carlo Carnaghi, Maria Chiara Tronconi, Chiara Gerardi, Francesca Galli, Irene Floriani, Annarita Destro, Carlotta Raschioni, Roberto Labianca, Armando Santoro	9
6	Association with programmed death ligand-1 (PDL-1) expression and Helicobacter Pylori infection in patients with non-diffuse type gastric carcinoma 2015 ·Annals of Oncology ·Maria Di Bartolomeo, Alessandro Pellegrinelli, Roberto Iacovelli, Filippo Pietrantonio, Rosa Berenato, M. Caporale, Monica Niger, Maria Aurelia Barbera, Roberto Labianca, (unknown), Gerardo Rosati, Donato Nitti, C. Boni, D. Amadori, Maurizio Cantore, Filippo de Braud, Emilio Bajetta	2
7	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC) 2014 ·Journal of Immunotherapy ·Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, Camillo Porta, Roberta Camisa, Luca Braglia, Gianluca Tomasello, Augusto Vaglio, Roberto Labianca, Ermanno Rondini, Roberto Sabbatini, Giuseppe Nastasi, Fabrizio Artioli, (unknown), (unknown), Debora Pezzuolo, Elena Oliva, Federico Alberici, Carlo Buzio	59
8	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set 2012 ·Journal of Clinical Oncology ·Joleen M. Hubbard, David M. Thomas, Greg Yothers, Erin Green, Charles D. Blanke, Michael J. O’Connell, Roberto Labianca, Qian Shi, Archie Bleyer, Aimery de Gramont, Daniel J. Sargent	32
9	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Daniel J. Sargent, Silvia Marsoni, Geneviève Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French, Brian Kabat, Nathan R. Foster, Valter Torri, Christine Ribic, Axel Grothey, Malcolm Moore, Alberto Zaniboni, J. F. Seitz, Frank Sinicrope, Steven Gallinger	1114
10	Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial 2010 ·Annals of Oncology ·A. Roth, Dirk Klingbiel, Ping Yan, Roberto Fiocca, Mauro Delorenzi, Roberto Labianca, David Cunningham, Eric Van Cutsem, Fred T. Bosman, Sabine Tejpar	2
11	Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up 2010 ·Annals of Oncology ·Roberto Labianca, Bernard Nordlinger, Giordano Beretta, Antoine Brouquet, Andrés Cervantes	253
12	Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial 2009 ·Annals of Oncology ·A. Roth, Sabine Tejpar, Ping Yan, Roberto Fiocca, Dirk Klingbiel, Mauro Delorenzi, Damien Dietrich, Roberto Labianca, David Cunningham, Eric Van Cutsem, Fred T. Bosman	7
13	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy 2008 ·Lung Cancer ·Marcello Tiseo, Cesare Gridelli, Stefano Cascinu, Lucio Crinò, Franco Vito Piantedosi, Francesco Grossi, Alba A. Brandes, Roberto Labianca, Salvatore Siena, D. Amoroso, Ornella Belvedere, (unknown), Alessandra Bearz, Paola Venturino, Andrea Ardizzoni	20
14	Chemioterapia nel sarcoma di Kaposi mediterraneo: 20 anni di esperienza 2000 ·Redia-Giornale Di Zoologia ·L. Brambilla, Roberto Labianca, Silvia Fossati, Silvia Mariel Ferrucci, (unknown), V. Boneschi	1
15	Errata: Treatment of colorectal cancer: Current guidelines and future prospects for drug therapy (Drugs (1997) 53 (593-607)) 1997 ·Drugs ·Roberto Labianca, M.A. Pessi, (unknown)	9
16	Treatment of Colorectal Cancer 1997 ·Drugs ·Roberto Labianca, M.A. Pessi, (unknown)	60
17	High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study 1997 ·Annals of Oncology ·Roberto Labianca, Stefano Cascinu, L. Frontini, Sandro Barni, Giammaria Fiorentini, G. Comella, (unknown), Ornella Gottardi, Ermenegildo Arnoldi, Cristina Oliani, Mary Duro, Giovanni Pavanato, G. Martignoni, (unknown), E. Piazza, (unknown), R. Valsecchi, G. Pancera	20
18	Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study 1995 ·British Journal of Cancer ·(unknown), (unknown), Giorgio Pizzocaro, Luigi Piva, (unknown), (unknown), (unknown), Massimo Meregalli, Federico Lombardi, (unknown), (unknown), Roberto Labianca, G Luporini	16
19	Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma 1995 ·European Journal of Dermatology ·L. Brambilla, Roberto Labianca, Silvia Fossati, V. Boneschi, Silvia Mariel Ferrucci, Marigrazia Clerici, (unknown)	5
20	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group 1993 ·Cancer ·Emilio Bajetta, Nicoletta Zilembo, Maria Di Bartolomeo, Angelo Di Leo, Silvana Pilotti, Anna Maria Bochicchio, Maria Rita Castellani, Roberto Buzzoni, Luigi Celio, Luigi Dogliotti, G. Pinotti, Enrico Aitini, Roberto Labianca, A. Fornasiero, (unknown), (unknown), P. Nelli, Luigi Mariani	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact